Article

Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis

Klinikum Augsburg, Augsberg, Bavaria, Germany
Journal of Clinical Oncology (Impact Factor: 17.88). 09/2003; 21(15):2883-8. DOI: 10.1200/JCO.2003.07.116
Source: PubMed

ABSTRACT Low-dose interferon alfa (IFNalpha) has been shown to have limited effects in the adjuvant treatment of patients with intermediate- and high-risk primary melanoma. We hypothesized that a combination regimen with low-dose interleukin-2 (IL-2) may improve survival prospects in these patients.
After wide excision of primary melanoma without clinically detectable lymph node metastasis (pT3 to 4, cN0, M0), 225 patients from 10 participating centers were randomly assigned to receive either subcutaneous low-dose IFNalpha2b (3 million international units [MU]/m2/d, days 1 to 7, week 1; three times weekly, weeks 3 to 6, repeated all 6 weeks) plus IL-2 (9 MU/m2/d, days 1 to 4, week 2 of each cycle) for 48 weeks, or observation alone. The primary end point was prolongation of a relapse-free interval.
Of the 225 enrolled patients, 223 were found to be eligible. Median follow-up time was 79 months. All evaluated prognostic factors were well balanced between the two arms of the study. Relapses were noticed in 36 of 113 patients treated with IFNalpha2b plus IL-2 and in 34 of 110 patients with observation alone. Five-year disease-free survival of those who had routine surgery supplemented by IFNalpha2b and IL-2 treatment was 70.1% (95% confidence interval [CI], 61.3% to 78.9%), compared with 69.9% in those receiving surgery and observation alone (95% CI, 60.7% to 79.1%) in the intention-to-treat analysis. Evaluation of the overall survival did not show any difference between treated and untreated melanoma patients (P =.93).
Adjuvant treatment of intermediate- and high-risk melanoma patients with low-dose IFNalpha2b and IL-2 is safe and well tolerated by most patients, but it does not improve disease-free or overall survival.

0 Followers
 · 
64 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Zusammenfassung Durch den fehlenden Wirksamkeitsnachweis der konventionellen Chemotherapie in der adjuvanten Situation sind rekombinante Interferone in den Mittelpunkt allen Interesses gerückt. Die adjuvante Interferontherapie bei Patienten mit Hochrisikomelanom ist in den noch resektablen Tumorstadien angebracht. Interferon α2a und Interferon α2b sind bisher die einzigen Substanzen, die für die adjuvante Melanomsituation zugelassen sind. Der Beitrag gibt einen Überblick zu aktuellen Behandlungsmöglichkeiten und effektivem Therapiemanagement. Durch den fehlenden Nachweis einer Wirksamkeit einer konventionellen Chemotherapie in der adjuvanten Situation rückten nach der ursprünglichen Verwendung von unspezifischen Immunstimulanzien rekombinante Interferone in den Mittelpunkt allen Interesses. Bis zum heutigen Zeitpunkt sind mit Interferon α2a (Roferon®-A) und Interferon α2b (Intron® A) nur 2 Substanzen verfügbar, die für die adjuvante Melanomsituation aufgrund der nachgewiesenen Effizienz eine Zulassung erhalten haben.). Die Verbindung von klassischen Interferonmolekülen mit Polyethylenglykol (PEG) sorgt für eine deutlich verlängerte Halbwertszeit des pegylierten Interferons im Vergleich zum konventionellen Interferon im peripheren Blut. Ein weiterer Vorteil liegt in der nur einmal wöchentlichen subkutanen Applikation. Pegylierte Interferone werden derzeit im Rahmen von prospektiv-randomisierten Studien bei Hochrisikomelanompatienten hinsichtlich ihrer Wirksamkeit und Toxizität überprüft.
    best practice onkologie 04/2007; 2(2):4-13. DOI:10.1007/s11654-007-0014-7
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND Systemic agents are used in melanoma for adjuvant therapy and to treat metastatic disease. Currently, interferon-alpha is the only agent approved for adjuvant therapy. Six drugs are FDA approved for metastatic disease: dacarbazine, interleukin-2 (IL-2), vemurafenib, ipilimumab, dabrafenib, and trametinib. Vemurafenib and ipilimumab were approved in 2011, whereas dabrafenib and trametinib were approved in 2013. OBJECTIVE This review will update the practicing dermatologist on the differences in efficacy, adverse events, and cost of systemic therapies available for the treatment of melanoma. MATERIALS AND METHODS This article is a review of the current literature on systemic therapies for advanced melanoma. Key search words included "advanced melanoma," "systemic therapy," and "adjuvant therapy" with particular focus on the past 20 years. RESULTS Before 2011, dacarbazine and IL-2 were the only FDA approved therapies for metastatic melanoma, and IFN-alpha is the only approved agent for adjuvant therapy. The new agents vemurafenib, ipilimumab, dabrafenib, and trametinib are the first to have improved overall survival in Phase III studies in comparison with other systemic therapies. CONCLUSION Despite new developments, there remains a significant need for better therapies with improved long-term efficacy and decreased toxicity.
    Dermatologic Surgery 07/2014; 40(9). DOI:10.1097/01.DSS.0000452626.09513.55 · 1.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The 2006 vintage leads to decreased enthusiasm in medical oncology, compared to the amazing 2005. One notable exception is the marketing of sunitinib and sorafenib, two agents which increase remarkably the chances of benefiting renal cell cancer patients. Several of the reviewed papers indicate the need to better target cancer treatment, including chemotherapy. One may hope that the near future will deliver on this, leading to an increased treatment effectiveness and decreased exposure to unjustified toxicity.
    The Lancet 11/1971; 298(7733):1100. DOI:10.1016/S0140-6736(71)90427-2 · 39.21 Impact Factor

Full-text

Download
73 Downloads
Available from
May 28, 2014